Treatment of skeletal involvement in neoplastic bone diseases.
Skeletal complications are frequent and increase morbidity dramatically in patients with malignancies. The role of bone resorption has been stressed leading to a key role for osteoclasts in the bone lesions. Specific and sensitive markers of bone resorption are now available. Bisphosphonates, powerful inhibitors of osteoclasts, can benefit patients with neoplastic bone diseases.
Roux
C
C
Centre d'Evaluation des Maladies Osseuses, Hopital Cochin, Université René Descartes, Paris, France.
Ravaud
P
P
D015519:Bone Density / Q000187:drug effects; D001859:Bone Neoplasms / Q000628:therapy*; D001862:Bone Resorption / Q000517:prevention & control; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology / Q000528:radiation effects; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy; D010146:Pain / Q000188:drug therapy
D004164:Diphosphonates